Literature DB >> 26100588

Utility of Routine Exercise Testing to Detect Rate-Related QRS Widening in Patients Without Structural Heart Disease on Class Ic Antiarrhythmic Agents (Flecainide and Propafenone).

Srikanth Vallurupalli1, Naga Venkata K Pothineni2, Abhishek Deshmukh3, Hakan Paydak2.   

Abstract

Class Ic antiarrhythmic agents are effective in the treatment of various atrial tachyarrhythmias. They are known to cause rate-related QRS widening in the presence of structural heart disease, which can lead to life-threatening arrhythmias. The role of routine exercise electrocardiography in patients without structural heart disease is unknown. All patients initiated on class Ic antiarrhythmic agents and who had exercise electrocardiography performed from June 2009 to June 2013 were included. Symptom-limited treadmill electrocardiography was performed to detect significant QRS widening at peak exercise (defined as an increase of >25% of baseline QRS). Fifty-six patients were included in the study. All patients were screened for structural heart disease before initiation of the medication. Significant QRS widening and atrial tachycardia occurred in a single patient, which terminated with cessation of exercise. This patient had a history of tachycardia-mediated cardiomyopathy with normalization of ejection fraction 3 years before being placed on flecainide. In conclusion, routine exercise testing to detect QRS widening is not warranted in patients with no structural heart disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26100588     DOI: 10.1016/j.amjcard.2015.05.039

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

Review 1.  Atrial Fibrillation Management: A Comprehensive Review with a Focus on Pharmacotherapy, Rate, and Rhythm Control Strategies.

Authors:  Jordan L Lacoste; Thomas W Szymanski; Juan Carlo Avalon; Galen Kabulski; Utkarsh Kohli; Nassir Marrouche; Atul Singla; Sudarshan Balla; Arshad Jahangir
Journal:  Am J Cardiovasc Drugs       Date:  2022-03-30       Impact factor: 3.283

2.  Initiation and outcomes with Class Ic antiarrhythmic drug therapy.

Authors:  Xu Gao; Avirup Guha; Benjamin Buck; Dilesh Patel; Melissa J Snider; Michael Boyd; Muhammad Afzal; Auroa Badin; Hemant Godara; Zhenguo Liu; Jaret Tyler; Raul Weiss; Steven Kalbfleisch; John Hummel; Ralph Augostini; Mahmoud Houmsse; Emile G Daoud
Journal:  Indian Pacing Electrophysiol J       Date:  2017-12-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.